# TABLES AND REFERENCES
## For: Elevated Lipid Metabolism Defines an Immunosuppressive Melanoma Subtype

---

## TABLES

### Table 1. Clinical and Pathological Characteristics of TCGA-SKCM Cohort

| Characteristic | Overall (n=472) | Low Lipid (n=236) | High Lipid (n=236) | P-value |
|---|---|---|---|---|
| **Age, years** | | | | |
| Median (range) | 58 (15-90) | 57 (15-88) | 60 (18-90) | 0.082 |
| <50 | 125 (26.5%) | 68 (28.8%) | 57 (24.2%) | |
| 50-65 | 198 (41.9%) | 102 (43.2%) | 96 (40.7%) | |
| >65 | 149 (31.6%) | 66 (28.0%) | 83 (35.2%) | 0.15 |
| **Sex** | | | | |
| Male | 297 (62.9%) | 145 (61.4%) | 152 (64.4%) | 0.51 |
| Female | 175 (37.1%) | 91 (38.6%) | 84 (35.6%) | |
| **Pathologic Stage** | | | | |
| Stage I | 78 (16.5%) | 46 (19.5%) | 32 (13.6%) | |
| Stage II | 69 (14.6%) | 40 (16.9%) | 29 (12.3%) | |
| Stage III | 208 (44.1%) | 98 (41.5%) | 110 (46.6%) | |
| Stage IV | 117 (24.8%) | 52 (22.0%) | 65 (27.5%) | 0.089 |
| Stage I/II | 147 (31.1%) | 86 (36.4%) | 61 (25.8%) | |
| Stage III/IV | 325 (68.9%) | 150 (63.6%) | 175 (74.2%) | 0.014* |
| **Primary vs. Metastatic** | | | | |
| Primary | 104 (22.0%) | 58 (24.6%) | 46 (19.5%) | 0.19 |
| Metastatic | 368 (78.0%) | 178 (75.4%) | 190 (80.5%) | |
| **BRAF Mutation Status** | | | | |
| Wild-type | 258 (54.7%) | 126 (53.4%) | 132 (55.9%) | 0.58 |
| V600E/K Mutant | 214 (45.3%) | 110 (46.6%) | 104 (44.1%) | |
| **Follow-up, years** | | | | |
| Median (IQR) | 3.2 (1.4-5.8) | 3.8 (1.8-6.5) | 2.6 (1.2-4.9) | 0.003* |
| **Overall Survival Status** | | | | |
| Alive | 275 (58.3%) | 155 (65.7%) | 120 (50.8%) | 0.001* |
| Deceased | 197 (41.7%) | 81 (34.3%) | 116 (49.2%) | |

*Statistically significant (p < 0.05); P-values from chi-squared test (categorical) or Wilcoxon test (continuous)

---

### Table 2. Univariate Cox Regression Analysis of Lipid Metabolism Genes and Clinical Variables

| Variable | Hazard Ratio | 95% CI | P-value |
|---|---|---|---|
| **Lipid Metabolism Genes (High vs. Low)** | | | |
| FASN | 1.42 | 1.08-1.87 | 0.024* |
| ACACA | 1.38 | 1.04-1.82 | 0.041* |
| SCD | 1.28 | 0.98-1.68 | 0.073 |
| ELOVL6 | 1.19 | 0.89-1.58 | 0.15 |
| FADS1 | 1.15 | 0.86-1.54 | 0.19 |
| FADS2 | 1.22 | 0.91-1.63 | 0.12 |
| ACLY | 1.26 | 0.95-1.67 | 0.086 |
| SREBF1 | 1.35 | 1.02-1.78 | 0.036* |
| **Lipid Signature (High vs. Low)** | 1.68 | 1.13-2.49 | 0.011* |
| **Clinical Variables** | | | |
| Age (per 10-year increase) | 1.22 | 1.11-1.35 | <0.001* |
| Sex (Male vs. Female) | 1.08 | 0.79-1.47 | 0.62 |
| Stage (III/IV vs. I/II) | 2.58 | 1.86-3.59 | <0.001* |
| Primary vs. Metastatic | 2.11 | 1.42-3.13 | <0.001* |
| BRAF mutation (Mutant vs. WT) | 0.88 | 0.66-1.16 | 0.35 |

*Statistically significant (p < 0.05)

---

### Table 3. Multivariate Cox Regression Analysis

| Variable | Hazard Ratio | 95% CI | P-value |
|---|---|---|---|
| **Model 1: Clinical Variables Only** | | | |
| Age (per 10-year increase) | 1.18 | 1.07-1.31 | 0.002* |
| Sex (Male vs. Female) | 1.12 | 0.82-1.53 | 0.478 |
| Stage (III/IV vs. I/II) | 2.41 | 1.73-3.36 | <0.001* |
| **C-index** | **0.68** | 0.64-0.72 | |
| | | | |
| **Model 2: Clinical + Lipid Signature** | | | |
| Lipid Signature (High vs. Low) | 1.72 | 1.15-2.58 | 0.008* |
| Age (per 10-year increase) | 1.16 | 1.05-1.29 | 0.004* |
| Sex (Male vs. Female) | 1.09 | 0.80-1.49 | 0.588 |
| Stage (III/IV vs. I/II) | 2.28 | 1.63-3.18 | <0.001* |
| **C-index** | **0.73** | 0.69-0.77 | |
| **Likelihood Ratio Test** | | | **p = 0.006*** |

*Statistically significant (p < 0.05); C-index = concordance index

---

### Table 4. Immune Cell Infiltration Comparison Between High and Low Lipid Metabolism Groups

| Immune Cell Type | Low Lipid Mean (SD) | High Lipid Mean (SD) | Fold Change | P-value |
|---|---|---|---|---|
| **T Cell Populations** | | | | |
| CD8+ T cells | 0.18 (0.10) | 0.12 (0.08) | 0.67 | <0.01** |
| CD4+ naive T cells | 0.08 (0.05) | 0.06 (0.04) | 0.75 | 0.04* |
| CD4+ memory resting T cells | 0.14 (0.07) | 0.12 (0.06) | 0.86 | 0.12 |
| CD4+ memory activated T cells | 0.06 (0.04) | 0.05 (0.03) | 0.83 | 0.19 |
| Regulatory T cells (Tregs) | 0.05 (0.04) | 0.09 (0.06) | 1.80 | <0.01** |
| Follicular helper T cells | 0.04 (0.03) | 0.03 (0.02) | 0.75 | 0.08 |
| **Macrophage Populations** | | | | |
| M0 Macrophages | 0.11 (0.08) | 0.10 (0.07) | 0.91 | 0.34 |
| M1 Macrophages | 0.13 (0.07) | 0.08 (0.05) | 0.62 | <0.05* |
| M2 Macrophages | 0.09 (0.06) | 0.14 (0.08) | 1.56 | <0.05* |
| **Other Immune Cells** | | | | |
| NK cells resting | 0.05 (0.04) | 0.03 (0.02) | 0.60 | 0.01* |
| NK cells activated | 0.02 (0.02) | 0.01 (0.01) | 0.50 | 0.02* |
| B cells naive | 0.03 (0.03) | 0.02 (0.02) | 0.67 | 0.11 |
| B cells memory | 0.02 (0.02) | 0.01 (0.01) | 0.50 | 0.06 |
| Plasma cells | 0.04 (0.04) | 0.03 (0.03) | 0.75 | 0.15 |
| Dendritic cells resting | 0.03 (0.02) | 0.02 (0.02) | 0.67 | 0.09 |
| Dendritic cells activated | 0.02 (0.02) | 0.01 (0.01) | 0.50 | 0.03* |
| Mast cells resting | 0.02 (0.02) | 0.02 (0.02) | 1.00 | 0.98 |
| Mast cells activated | 0.01 (0.01) | 0.01 (0.01) | 1.00 | 0.86 |
| Monocytes | 0.06 (0.04) | 0.05 (0.03) | 0.83 | 0.22 |
| Neutrophils | 0.03 (0.03) | 0.03 (0.03) | 1.00 | 0.75 |
| Eosinophils | 0.01 (0.01) | 0.01 (0.01) | 1.00 | 0.92 |
| **Total Immune Infiltration** | 0.85 (0.21) | 0.71 (0.19) | 0.84 | 0.0245* |

*p < 0.05; **p < 0.01; P-values from Wilcoxon rank-sum test

---

## REFERENCES

1. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763-777.

2. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000;16(3):202-208.

3. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153-161.

4. Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36-50.

5. Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218(1):e20201606.

6. Hao Y, Li D, Xu Y, Ouyang J, Wang Y, Zhang Y, et al. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data. BMC Bioinformatics. 2019;20(Suppl 7):195.

7. RÃ¶hrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732-749.

8. CornKC, Coussens LM, Hanahan D, Casanovas O. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci. 2018;21(2):228-238.

9. Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab. 2020;31(1):62-76.

10. Wu H, Han Y, Rodriguez Sillke Y, Deng H, Siddiqui S, Treese C, et al. Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages. EMBO Mol Med. 2019;11(11):e10698.

11. Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392(10151):971-984.

12. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626-636.

13. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-1546.

14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.

15. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27-47.

16. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer. 2013;13(4):227-232.

17. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189.

18. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279(15):2610-2623.

19. Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013;6(6):1353-1363.

20. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010;6(4):551-562.

21. Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, et al. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell Death Discov. 2017;3:17058.

22. Wellbrock C, Arozarena I. The complexity of the ERK/MAP-kinase pathway and the treatment of melanoma skin cancer. Front Cell Dev Biol. 2016;4:33.

23. Chen WC, Wang CY, Hung YH, Weng TY, Yen MC, Lai MD. Systematic analysis of gene expression alterations and clinical outcomes for long-chain acyl-coenzyme A synthetase family in cancer. PLoS One. 2016;11(5):e0155660.

24. Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 2017;20(3):303-314.

25. Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 2016;22(10):1108-1119.

26. Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, et al. Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol Cancer Ther. 2011;10(3):427-436.

27. Traves PG, Lopez-Fontal R, Cuadrado A, Luque A, Rojo AI, Faraldos JA, et al. Identification of a novel regulatory mechanism of macrophage phenotype by stearoyl-CoA desaturase. FASEB J. 2012;26(1):144-154.

28. Heidenreich S, Witte N, Weber P, Goehring I, Tolkachov A, von Loeffelholz C, et al. Retinol saturase coordinates liver metabolism by regulating ChREBP activity. Nat Commun. 2017;8:384.

29. Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017;27(11):863-875.

30. Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593(7858):282-288.

31. Jiang M, Wu N, Xu B, Chu Y, Li X, Su S, et al. Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Theranostics. 2019;9(18):5359-5373.

32. Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270-274.

33. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010;16(8):880-886.

34. Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res. 2015;3(11):1236-1247.

35. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229-1241.

36. Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162(6):1217-1228.

37. O'Sullivan D, van der Windt GJ, Huang SC, Curtis JD, Chang CH, Buck MD, et al. Memory CD8+ T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity. 2014;41(1):75-88.

38. Ma X, Xiao L, Liu L, Ye L, Su P, Bi E, et al. CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33(5):1001-1012.

39. Xu S, Chaudhary O, Rodriguez-Morales P, Sun X, Chen D, Zappasodi R, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity. 2021;54(7):1561-1577.

40. Lim SA, Wei J, Nguyen TM, Shi H, Su W, Palacios G, et al. Lipid signalling enforces functional specialization of Treg cells in tumours. Nature. 2021;591(7849):306-311.

41. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887-904.

42. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369-382.

43. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399-416.

44. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.

45. Huang SC, Everts B, Ivanova Y, O'Sullivan D, Nascimento M, Smith AM, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol. 2014;15(9):846-855.

46. Nomura M, Liu J, Rovira II, Gonzalez-Hurtado E, Lee J, Wolfgang MJ, et al. Fatty acid oxidation in macrophage polarization. Nat Immunol. 2016;17(3):216-217.

47. Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, et al. alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18(9):985-994.

48. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186(6):3299-3303.

49. Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. 2014;20(11):1327-1333.

50. Angelin A, Gil-de-Gomez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 2017;25(6):1282-1293.

51. Wang H, Franco F, Tsui YC, Xie X, Trefny MP, Zappasodi R, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020;21(3):298-308.

52. Field CS, Baixauli F, Kyle RL, Puleston DJ, Cameron AM, Sanin DE, et al. Mitochondrial integrity regulated by lipid metabolism is a cell-intrinsic checkpoint for Treg suppressive function. Cell Metab. 2020;31(2):422-437.

53. Vivas-Garcia Y, Falletta P, Liebing J, Louphrasitthiphol P, Feng Y, Chauhan J, et al. Lineage-restricted regulation of SCD and fatty acid saturation by MITF controls melanoma phenotypic plasticity. Mol Cell. 2020;77(1):120-137.

54. Falchi
